TSE:CPH Cipher Pharmaceuticals (CPH) Stock Price, News & Analysis → Trump’s “Tax Free” Retirement Strategy (From Gold Safe Exchange) (Ad) Free CPH Stock Alerts C$9.39 +0.44 (+4.92%) (As of 02:06 PM ET) Add Compare Share Share Today's RangeC$9.25▼C$10.3350-Day RangeC$7.08▼C$9.5052-Week RangeC$3.21▼C$10.33Volume86,761 shsAverage Volume38,424 shsMarket CapitalizationC$226.39 millionP/E Ratio8.54Dividend YieldN/APrice TargetC$8.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlines Get Cipher Pharmaceuticals alerts: Email Address Cipher Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside20.9% DownsideC$8.00 Price TargetShort InterestN/ADividend StrengthN/ASustainabilityN/ANews Sentiment0.30Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.67 out of 5 stars 1.5 Analyst's Opinion Consensus RatingCipher Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageCipher Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.Read more about Cipher Pharmaceuticals' stock forecast and price target. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for CPH. Previous Next 0.0 Dividend Strength Dividend YieldCipher Pharmaceuticals does not currently pay a dividend.Dividend GrowthCipher Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CPH. Previous Next 2.9 News and Social Media Coverage News SentimentCipher Pharmaceuticals has a news sentiment score of 0.30. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.45 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Cipher Pharmaceuticals this week, compared to 0 articles on an average week.Search Interest1 people have searched for CPH on MarketBeat in the last 30 days. MarketBeat Follows1 people have added Cipher Pharmaceuticals to their MarketBeat watchlist in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Cipher Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders44.51% of the stock of Cipher Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 1.12% of the stock of Cipher Pharmaceuticals is held by institutions.Read more about Cipher Pharmaceuticals' insider trading history. Previous Next 1.3 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Cipher Pharmaceuticals is 9.19, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 145.80.Price to Earnings Ratio vs. SectorThe P/E ratio of Cipher Pharmaceuticals is 9.19, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 189.03.Price to Book Value per Share RatioCipher Pharmaceuticals has a P/B Ratio of 3.01. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Cipher Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Gold Safe ExchangeTrump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.Protect your retirement savings from the inevitable devaluation of the dollar… About Cipher Pharmaceuticals Stock (TSE:CPH)Cipher Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. It offers Epuris (isotretinoin), an oral retinoid indicated for the treatment of severe nodular and/or inflammatory acne, acne conglobate, and recalcitrant acne; Actikerall, a topical solution indicated for the treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis (Grade I/II) of the face, forehead, and balding scalp; Ozanex for the topical treatment of impetigo; Vaniqa, a topical cream for the slowing of the growth of unwanted facial hair in women; Durela, an opioid analgesic for the management of moderate to moderately severe pain in adults; Brinavess for the rapid conversion of onset atrial fibriallation to sinus rhythm in adults; and Aggrastat, a reversible GP IIb/IIIa inhibitor for use in patients with Acute Coronary Syndrome. The company's licensed products comprise Absorica, an oral retinoid indicated for the treatment of f severe nodular and/or inflammatory acne, acne conglobate and recalcitrant acne; Lipofen, which is indicated as adjunctive therapy to diet to reduce elevated LDL-C, total-C, triglycerides, and Apo B, and to increase HDL-C, as well as to reduce triglycerides in adult patients; and Conzip, an opioid agonist indicated for the management of moderate to moderately severe chronic pain in adults. Its pipeline products include MOB-015, a topical formulation of terbinafine, which is in phase 3 clinical trial for treatment of onychomycosis; CF-101 (Piclidenoson) that is in phase 3 clinical trial for severe plaque psoriasis and rheumatoid arthritis; and DTR-001, a tattoo removal cream, which is in pre-clinical stage. Cipher Pharmaceuticals Inc. was founded in 2000 and is headquartered in Mississauga, Canada.Read More CPH Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CPH Stock News HeadlinesMay 4, 2024 | americanbankingnews.comCipher Pharmaceuticals (TSE:CPH) Share Price Passes Above 50 Day Moving Average of $8.28April 28, 2024 | theglobeandmail.comCipher Pharmaceuticals: Stocks Overvalued by Analyst Consensus on TSX (CPH)May 10, 2024 | Gold Safe Exchange (Ad)Trump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.April 27, 2024 | theglobeandmail.comClosing Bell: Cipher Pharmaceuticals Inc flat on Friday (CPH)April 3, 2024 | ca.finance.yahoo.comStocks in play: Cipher PharmaceuticalsMarch 28, 2024 | theglobeandmail.comCipher Pharmaceuticals: Top 25 Performing Stocks Year-to-Date on Toronto Stock Exchange (CPH)March 17, 2024 | seekingalpha.comCipher Pharmaceuticals (CPHRF) Q4 2023 Earnings Call TranscriptMarch 17, 2024 | investing.comEarnings call: Cipher Pharmaceuticals outlines growth and financialsMay 10, 2024 | Gold Safe Exchange (Ad)Trump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.January 5, 2024 | morningstar.comCipher Pharmaceuticals Inc CPHJanuary 3, 2024 | finance.yahoo.comCipher Pharmaceuticals Inc (PHE.MU)November 24, 2023 | finance.yahoo.comCipher Pharmaceuticals Announces Change of AuditorNovember 24, 2023 | benzinga.comCipher Pharmaceuticals Stock (OTC:CPHRF) Dividends: History, Yield and DatesNovember 15, 2023 | finance.yahoo.comCipher Pharmaceuticals Inc.'s (TSE:CPH) 23% gain last week benefited both individual investors who own 56% as well as insidersOctober 27, 2023 | finance.yahoo.comCipher Pharmaceuticals Schedules Q3 2023 Earnings Release and Conference CallSeptember 5, 2023 | finance.yahoo.comCipher Pharmaceuticals Announces Intention to Commence Substantial Issuer Bid, Aggregate Price up to $6 Million Canadian DollarsAugust 10, 2023 | finance.yahoo.comCipher Pharmaceuticals Releases Q2 2023 Results, Announces Launch of Epuris in MexicoJuly 28, 2023 | finance.yahoo.comCipher Pharmaceuticals Schedules Q2 2023 Earnings Release and Conference CallJuly 5, 2023 | finance.yahoo.comCipher Partner, Moberg Pharma Announces Approval for MOB-015 in the European UnionJune 21, 2023 | finance.yahoo.comCipher Pharmaceuticals Announces Results of Annual and Special Meeting of ShareholdersMay 4, 2023 | finance.yahoo.comCipher Pharmaceuticals Schedules Q1 2023 Earnings Release and Conference CallApril 26, 2023 | theglobeandmail.comClosing Bell: Cipher Pharmaceuticals Inc flat on Tuesday (CPH)April 20, 2023 | theglobeandmail.comClosing Bell: Cipher Pharmaceuticals Inc flat on Thursday (CPH)April 18, 2023 | finanznachrichten.deBloom Burton & Co. Inc.: Cipher Pharmaceuticals to Present at the 2023 Bloom Burton & Co. Healthcare Investor ConferenceApril 18, 2023 | theglobeandmail.comClosing Bell: Cipher Pharmaceuticals Inc up on Tuesday (CPH)April 18, 2023 | finance.yahoo.comCipher Pharmaceuticals to Present at the 2023 Bloom Burton & Co. Healthcare Investor ConferenceApril 14, 2023 | theglobeandmail.comClosing Bell: Cipher Pharmaceuticals Inc up on Friday (CPH)See More Headlines Receive CPH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cipher Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/14/2024Today5/10/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeTSE SectorMedical Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A Current SymbolTSE:CPH Previous SymbolTSE:DND CUSIPN/A CIKN/A Webwww.cipherpharma.com Phone+1-905-6025840FaxN/AEmployees5Year FoundedN/APrice Target and Rating Average Stock Price TargetC$8.00 High Stock Price TargetC$8.00 Low Stock Price TargetC$8.00 Potential Upside/Downside-10.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)C$1.10 Trailing P/E Ratio8.14 Forward P/E Ratio14.33 P/E GrowthN/ANet IncomeC$20.38 million Net Margins96.32% Pretax MarginN/A Return on Equity28.19% Return on Assets8.06% Debt Debt-to-Equity Ratio0.44 Current Ratio9.19 Quick Ratio2.67 Sales & Book Value Annual SalesC$21.16 million Price / Sales10.20 Cash FlowC$2.54 per share Price / Cash Flow3.53 Book ValueC$3.36 per share Price / Book2.66Miscellaneous Outstanding Shares24,110,000Free FloatN/AMarket CapC$215.78 million OptionableNot Optionable Beta1.04 The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report Key ExecutivesMr. Craig J. MullInterim CEO & Chairman of the BoardMr. Bryan JacobsChief Financial OfficerDr. Diane GajewczykVice President of Scientific & Medical AffairsMr. Emilio PrestiDirector of Sales & MarketingKey CompetitorsICC LabsCVE:ICCRIV CapitalTSE:RIVESSA PharmaCVE:EPILeaf MobileTSE:LEAFOrganigramTSE:OGIView All Competitors CPH Stock Analysis - Frequently Asked Questions Should I buy or sell Cipher Pharmaceuticals stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Cipher Pharmaceuticals in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CPH shares. View CPH analyst ratings or view top-rated stocks. What is Cipher Pharmaceuticals' stock price target for 2024? 1 analysts have issued 12 month price targets for Cipher Pharmaceuticals' shares. Their CPH share price targets range from C$8.00 to C$8.00. On average, they expect the company's stock price to reach C$8.00 in the next twelve months. This suggests that the stock has a possible downside of 20.9%. View analysts price targets for CPH or view top-rated stocks among Wall Street analysts. How have CPH shares performed in 2024? Cipher Pharmaceuticals' stock was trading at C$5.54 at the beginning of 2024. Since then, CPH stock has increased by 82.5% and is now trading at C$10.11. View the best growth stocks for 2024 here. When is Cipher Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 8th 2024. View our CPH earnings forecast. How were Cipher Pharmaceuticals' earnings last quarter? Cipher Pharmaceuticals Inc. (TSE:CPH) released its earnings results on Thursday, March, 14th. The company reported $0.41 EPS for the quarter, beating analysts' consensus estimates of $0.15 by $0.26. The business earned $6.70 million during the quarter, compared to the consensus estimate of $7.31 million. Cipher Pharmaceuticals had a trailing twelve-month return on equity of 28.19% and a net margin of 96.32%. What other stocks do shareholders of Cipher Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Cipher Pharmaceuticals investors own include Cipher Pharmaceuticals (CPHRF), Bellatrix Exploration (BXE), Aurora Cannabis (ACB), Aldeyra Therapeutics (ALDX), Allena Pharmaceuticals (ALNA), Catalyst Biosciences (CBIO), Crescent Point Energy (CPG) and Enbridge (ENB). How do I buy shares of Cipher Pharmaceuticals? Shares of CPH stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.Compare Top Brokerages Here. This page (TSE:CPH) was last updated on 5/10/2024 by MarketBeat.com Staff From Our Partners[Webinar] A Deep Dive into Options Volatility: Skew & Relative ValueOICThis 1 Biotech Stock has been shocking the marketsHuge AlertsTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaCharles Payne Demystifies OptionsUnstoppable ProsperityForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingYou need to know these two things about AI stocks ASAP…InvestorPlaceShocking: One AI startup's revenue could surge 4,735%Manward PressBiden Nomination CANCELED?The Freeport Society Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cipher Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
